197 related articles for article (PubMed ID: 25659819)
1. Rapamycin-induced G1 cell cycle arrest employs both TGF-β and Rb pathways.
Chatterjee A; Mukhopadhyay S; Tung K; Patel D; Foster DA
Cancer Lett; 2015 May; 360(2):134-40. PubMed ID: 25659819
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-β-dependent G1 cell cycle arrest.
Yellen P; Chatterjee A; Preda A; Foster DA
Cancer Lett; 2013 Jun; 333(2):239-43. PubMed ID: 23376634
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle.
Saqcena M; Patel D; Menon D; Mukhopadhyay S; Foster DA
Cell Cycle; 2015; 14(14):2285-92. PubMed ID: 25945415
[TBL] [Abstract][Full Text] [Related]
4. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1.
Averous J; Fonseca BD; Proud CG
Oncogene; 2008 Feb; 27(8):1106-13. PubMed ID: 17724476
[TBL] [Abstract][Full Text] [Related]
5. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.
Yellen P; Saqcena M; Salloum D; Feng J; Preda A; Xu L; Rodrik-Outmezguine V; Foster DA
Cell Cycle; 2011 Nov; 10(22):3948-56. PubMed ID: 22071574
[TBL] [Abstract][Full Text] [Related]
6. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
7. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.
Mita MM; Mita A; Rowinsky EK
Cancer Biol Ther; 2003; 2(4 Suppl 1):S169-77. PubMed ID: 14508096
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of insulin signaling and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1.
El-Chaâr D; Gagnon A; Sorisky A
Int J Obes Relat Metab Disord; 2004 Feb; 28(2):191-8. PubMed ID: 14970836
[TBL] [Abstract][Full Text] [Related]
9. Defective TGF-beta signaling sensitizes human cancer cells to rapamycin.
Gadir N; Jackson DN; Lee E; Foster DA
Oncogene; 2008 Feb; 27(8):1055-62. PubMed ID: 17700525
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin inhibits cdk4 activation, p 21(WAF1/CIP1) expression and G1-phase progression in transformed mouse fibroblasts.
Gaben AM; Saucier C; Bedin M; Barbu V; Mester J
Int J Cancer; 2004 Jan; 108(2):200-6. PubMed ID: 14639603
[TBL] [Abstract][Full Text] [Related]
11. Metformin induces G1 cell cycle arrest and inhibits cell proliferation in nasopharyngeal carcinoma cells.
Zhao L; Wen ZH; Jia CH; Li M; Luo SQ; Bai XC
Anat Rec (Hoboken); 2011 Aug; 294(8):1337-43. PubMed ID: 21717584
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms.
Biecker E; De Gottardi A; Neef M; Unternährer M; Schneider V; Ledermann M; Sägesser H; Shaw S; Reichen J
J Pharmacol Exp Ther; 2005 Jun; 313(3):952-61. PubMed ID: 15769867
[TBL] [Abstract][Full Text] [Related]
13. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E.
Fingar DC; Richardson CJ; Tee AR; Cheatham L; Tsou C; Blenis J
Mol Cell Biol; 2004 Jan; 24(1):200-16. PubMed ID: 14673156
[TBL] [Abstract][Full Text] [Related]
14. Carbon monoxide releasing molecule-2 CORM-2 represses global protein synthesis by inhibition of eukaryotic elongation factor eEF2.
Schwer CI; Stoll P; Rospert S; Fitzke E; Schallner N; Bürkle H; Schmidt R; Humar M
Int J Biochem Cell Biol; 2013 Feb; 45(2):201-12. PubMed ID: 23041477
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin: a new molecular target for breast cancer.
Mita MM; Mita A; Rowinsky EK
Clin Breast Cancer; 2003 Jun; 4(2):126-37. PubMed ID: 12864941
[TBL] [Abstract][Full Text] [Related]
16. The rapid activation of protein synthesis by growth hormone requires signaling through mTOR.
Hayashi AA; Proud CG
Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1647-55. PubMed ID: 17284572
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S
Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128
[TBL] [Abstract][Full Text] [Related]
18. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
Dudkin L; Dilling MB; Cheshire PJ; Harwood FC; Hollingshead M; Arbuck SG; Travis R; Sausville EA; Houghton PJ
Clin Cancer Res; 2001 Jun; 7(6):1758-64. PubMed ID: 11410517
[TBL] [Abstract][Full Text] [Related]
19. Everolimus induces G
Chen G; Ding XF; Bouamar H; Pressley K; Sun LZ
Am J Physiol Cell Physiol; 2019 Aug; 317(2):C244-C252. PubMed ID: 31116586
[TBL] [Abstract][Full Text] [Related]
20. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.
Dong J; Peng J; Zhang H; Mondesire WH; Jian W; Mills GB; Hung MC; Meric-Bernstam F
Cancer Res; 2005 Mar; 65(5):1961-72. PubMed ID: 15753396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
